Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

VERACYTE, INC. Director's Dealing 2021

Jun 8, 2021

31551_dirs_2021-06-08_c095af57-679c-443c-8430-3e80d5fad8fa.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERACYTE, INC. (VCYT)
CIK: 0001384101
Period of Report: 2021-06-04

Reporting Person: Kennedy Giulia C (Chief Scientific & Med Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-06-04 Common Stock M 4406 $5.98 Acquired 57218 Direct
2021-06-04 Common Stock M 3750 $20.21 Acquired 60968 Direct
2021-06-04 Common Stock S 1507 $33.279 Disposed 59461 Direct
2021-06-04 Common Stock S 2595 $34.3936 Disposed 56866 Direct
2021-06-04 Common Stock S 4979 $35.1702 Disposed 51887 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-06-04 Stock Option (right to buy) $5.98 M 4406 Disposed 2028-03-01 Common Stock (4406.0) Direct
2021-06-04 Stock Option (right to buy) $20.21 M 3750 Disposed 2029-02-27 Common Stock (3750.0) Direct

Footnotes

F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020.

F2: Represents weighted average sales price. Sale prices for the transactions range from $32.92 to $33.68. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

F3: Represents weighted average sales price. Sale prices for the transactions range from $33.93 to $34.93. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

F4: Represents weighted average sales price. Sale prices for the transactions range from $34.95 to $35.27. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

F5: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter

F6: The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.